Learn About Enrollment in a Clinical Trial Sponsored by Conformal
The Conformal Early Feasibility Study is an evaluation of the safety and performance of the Conformal LAA Seal (CLAAS). This is a prospective, multicenter, open-label, first-in-human study.
The study will enroll up to 45 adults aged 18 or older with documented non-valvular atrial fibrillation and high risk of stroke or systemic embolism, who have been advised to take oral anticoagulation therapy, but have appropriate reasons to seek a non-pharmacologic alternative.
There are other criteria for participation in this study. For more information, visit clinicaltrials.gov.
Catholic Medical Center
Manchester, New Hampshire
Contact: Elizabeth Cornelius, RN
Principal Investigator: Jamie Kim, M.D.
Columbia University Medical Center/NYPH
New York, New York
Contact: Efrain DeJesus
Principal Investigator: Robert Sommer, M.D.
Bryn Mawr Hospital
Bryn Mawr, Pennsylvania
Contact: Lisa Thome, MS
Principal Investigator: Sheetal Chandhok, M.D.
The Heart Hospital Baylor Plano
Contact: Gina Ortiz
Principal Investigator: Molly Szerlip, M.D.
Pacific Heart Institute
Santa Monica, CA
Contact: Crystal Ducharme
Principal Investigator: Shephal Doshi, M.D.